BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15811196)

  • 1. Diabetes and cardiovascular risk markers.
    Erdmann E
    Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic dyslipidaemia: insights for optimizing patient management.
    Vergès B
    Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids in type 2 diabetes.
    Laakso M
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA
    Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARgamma and atherosclerosis.
    Staels B
    Curr Med Res Opin; 2005; 21 Suppl 1():S13-20. PubMed ID: 15811195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
    Carmena R
    Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS
    Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.